Association of polypharmacy and potential drug-drug interactions with adverse treatment outcomes in older adults with advanced cancer.

ABSTRACT:

Background

Polypharmacy is common in older adults who are starting cancer treatment and is associated with an increased risk of potentially inappropriate medications (PIMs) and potential drug-drug interactions (PDIs). The authors evaluated the association of medication measures with adverse outcomes in older adults with advanced cancer who were receiving systemic therapy.

Methods

This secondary analysis from GAP 70+ Trial (ClinicalTrials.gov identifier NCT02054741; principal investigator, Supriya G. Mohile) enrolled patients aged 70 years and older with advanced cancer who planned to start a new treatment regimen (n = 718). Polypharmacy was assessed before the initiation of treatment and was defined as the concurrent use of eight or more medications. PIMs were categorized us

SUBMITTER: Mohamed MR 

PROVIDER: S-EPMC10958985 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature